QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Pluristem Therapeutics, Inc. (PSTI) Reports Latest Developments At Industry Conference 0 comments
    Jan 22, 2013 5:50 PM | about stocks: PSTI

    Pluristem Therapeutics, a leading developer of placenta-based cell therapies, announced that its senior scientists will present updated developments relating to the company's proprietary 3D cell expansion technology at the Scale-Up and Manufacturing of Cell-Based Therapies II Conference in San Diego, California, which is being held January 21-23, 2013. These innovations will be implemented in Pluristem's new state-of-the-art manufacturing facility for expansion of placental-derived mesenchymal-like Adherent Stromal Cells (ASCs).

    The following presentations will be made by Pluristem's team:

    • "Bioreactors in Cell Therapy, the Advantages of High-Throughput Culturing Technologies and the Downstream Challenges" - Ohad Karnieli PhD, MBA and VP of Development at Pluristem, will present Pluristem's new production line and demonstrate how the company has utilized high-throughput culturing to solve many of the problems related to the mass production of ASCs. Dr. Karnieli's presentation will be made available at the company's website .

    • "From Gene Expression to In Vivo Models - Characterization and Potential Therapeutic Properties of Placenta Derived Mesenchymal-Like Adherent Stromal Cells" - Eytan Abraham, PhD and Product Innovation Research Manager, will address the specific changes that occur in gene regulation and protein secretion when ASCs are grown in a 3D culturing phase and the biological changes and therapeutic advantages of implementing this technology in the mass expansion of ASCs use.

    Pluristem Therapeutics, a leading developer of placenta-based cell therapies, has a robust patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. Pluristem is focusing on the development of PLX (PLacental eXpanded) cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.

    For more information, visit pluristem.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: PSTI
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.